Michael Perelman
Overview
Explore the profile of Michael Perelman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
216
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Canning B, Liu Q, Tao M, DeVita R, Perelman M, Hay D, et al.
J Pharmacol Exp Ther
. 2021 Nov;
380(2):94-103.
PMID: 34782407
Studies performed in healthy smokers have documented a diminished responsiveness to tussive challenges, and several lines of experimental evidence implicate nicotine as an antitussive component in both cigarette smoke and...
2.
Ueberall M, Lorenzl S, Lux E, Voltz R, Perelman M
J Pain Res
. 2016 Aug;
9:571-85.
PMID: 27574463
Objective: Assessment of analgesic effectiveness, safety, and tolerability of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain (BTcP) in routine clinical practice. Methods: A prospective, open-label,...
3.
Torres L, Trinidad J, Calderon E, Benitez D, Perelman M
Int J Palliat Nurs
. 2015 Mar;
21(3):114-6.
PMID: 25815759
No abstract available.
4.
Watts P, Smith A, Perelman M
Drug Deliv Transl Res
. 2015 Mar;
3(1):75-83.
PMID: 25787867
Fentanyl, a potent opioid analgesic, is rapidly and efficiently absorbed from the nasal cavity, giving significant potential for nasally administered fentanyl to be used in pain management. Many reported clinical...
5.
Torres L, Revnic J, Knight A, Perelman M
J Palliat Med
. 2014 Sep;
17(10):1150-7.
PMID: 25211772
Background: Satisfaction with pain relief in patients with breakthrough pain in cancer (BTPc) has typically been assessed by overall efficacy without consideration of the rapidity of that response. Objective: To...
6.
Burton A, Filbet M, Knight A, Tayi R, Perelman M
J Community Support Oncol
. 2014 Jun;
12(3):99-103.
PMID: 24971415
Background: The management of breakthrough pain in patients with cancer (BTPc) generally includes an initial titration of breakthrough pain medication to an effective dose, followed by the use of that...
7.
Smith A, Perelman M, Hinchcliffe M
Hum Vaccin Immunother
. 2013 Dec;
10(3):797-807.
PMID: 24346613
The nasal route is attractive for the delivery of vaccines in that it not only offers an easy to use, non-invasive, needle-free alternative to more conventional parenteral injection, but it...
8.
Taylor D, Radbruch L, Revnic J, Torres L, Ellershaw J, Perelman M
J Pain Symptom Manage
. 2013 Oct;
47(6):1001-7.
PMID: 24128821
Context: As patients with cancer are living longer, there is a need to ensure that treatments used for palliative care are well tolerated and effective during long-term use. Objectives: To...
9.
Perelman M, Knight A
Int J Clin Pharmacol Ther
. 2013 Oct;
51(12):942-7.
PMID: 24120713
Objective: Fentanyl pectin nasal spray (FPNS) is approved for management of breakthrough pain in cancer. It is available in 100 and 400 μg strength products which allow for doses of...
10.